Antiretrovirals used to treat HIV-infected patients have the potential to adversely affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging concern among HIV-infected patients. Since boosted atazanavir and efavirenz are both considered preferred antiretrovirals a head to head comparison of their effects on serum lipids is needed.
Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda, Maryland, USA. aug151947@yahoo.com
